Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 8, 2010 - Issue 2
Submit an article Journal homepage
560
Views
70
CrossRef citations to date
0
Altmetric
Drug Profile

Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist

Davide Capodanno University of Florida College of Medicine, Jacksonville, FL, USA. [email protected]
,
Kodlipet Dharmashankar University of Florida College of Medicine, Jacksonville, FL, USA
&
Dominick J Angiolillo University of Florida College of Medicine, 655 West 8th Street, Jacksonville, FL 32209, USA. [email protected]
Pages 151-158 | Published online: 10 Jan 2014

Citations (70)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Marco Spagnolo, Dominick J. Angiolillo & Davide Capodanno. (2023) Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration. Expert Opinion on Drug Metabolism & Toxicology 19:11, pages 769-784.
Read now
Mattia Galli, Francesco Franchi, Fabiana Rollini, Larisa H Cavallari, Davide Capodanno, Filippo Crea & Dominick J Angiolillo. (2021) Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Review of Clinical Pharmacology 14:8, pages 963-978.
Read now
Dario Calderone, Davide Capodanno & Dominick J. Angiolillo. (2020) An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. Expert Review of Cardiovascular Therapy 18:8, pages 449-464.
Read now
Rocco P. Milluzzo, Gabriele A. Franchina, Davide Capodanno & Dominick J. Angiolillo. (2020) Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development. Expert Opinion on Investigational Drugs 29:6, pages 537-546.
Read now
Jae Youn Moon, Francesco Franchi, Fabiana Rollini, Jose R. Rivas Rios, Megha Kureti, Larisa H. Cavallari & Dominick J. Angiolillo. (2018) Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Review of Clinical Pharmacology 11:2, pages 151-164.
Read now
Piera Capranzano & Davide Capodanno. (2013) Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. Expert Review of Cardiovascular Therapy 11:3, pages 307-317.
Read now
Fabiana Rollini, Antonio Tello-Montoliu & Dominick J. Angiolillo. (2012) Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease. Platelets 23:7, pages 537-551.
Read now
Davide Capodanno, Corrado Tamburino & George Dangas. (2011) The optimal pharmacological formula for percutaneous coronary intervention. Expert Opinion on Pharmacotherapy 12:7, pages 1075-1086.
Read now

Articles from other publishers (62)

Bayan Moustafa & Fernando D. Testai. (2022) Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies. Current Neurology and Neuroscience Reports 22:11, pages 789-802.
Crossref
Lauren M. Weaver, Charles D. Loftin & Chang-Guo Zhan. (2022) Development of pharmacotherapies for abdominal aortic aneurysms. Biomedicine & Pharmacotherapy 153, pages 113340.
Crossref
Mattia Galli, Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini & Dominick J Angiolillo. (2022) Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention. Pharmacogenomics 23:13, pages 723-737.
Crossref
Piera Capranzano & Dominick J. Angiolillo. 2022. Interventional Cardiology. Interventional Cardiology 407 419 .
Yusuf Olgar, Erkan Tuncay, Deniz Billur & Belma Turan. (2021) Bimodal Effects of P2Y12 Antagonism on Matrix Metalloproteinase–Associated Contractile Dysfunction in İnsulin-Resistant Mammalian Heart. Biological Trace Element Research 200:5, pages 2195-2204.
Crossref
Ashis K. Mukherjee & Dhruba J. Chattopadhyay. (2022) Potential clinical applications of phytopharmaceuticals for the in‐patient management of coagulopathies in COVID ‐19 . Phytotherapy Research 36:5, pages 1884-1913.
Crossref
Zhiqiang Zhao, Xuanbo Zhang, Hongyuan Zhang, Xinzhu Shan, Meiyu Bai, Zhe Wang, Fujun Yang, Haotian Zhang, Qiming Kan, Bingjun Sun, Jin Sun, Zhonggui He & Cong Luo. (2021) Elaborately Engineering a Self‐Indicating Dual‐Drug Nanoassembly for Site‐Specific Photothermal‐Potentiated Thrombus Penetration and Thrombolysis. Advanced Science 9:4, pages 2104264.
Crossref
L.M. Camargo, P.C.T.M. Lima, K. Janot & I.L. Maldonado. (2021) Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives. American Journal of Neuroradiology 42:12, pages 2119-2126.
Crossref
Salia Farrokh, Kent Owusu, Lucia Rivera Lara, Katharine Nault, Ferdinand Hui & Brian Spoelhof. (2019) Neuro-Interventional Use of Oral Antiplatelets: A Survey of Neuro-Endovascular Centers in the United States and Review of the Literature. Journal of Pharmacy Practice 34:2, pages 207-215.
Crossref
Mo-Ran Sun, Hong-Liang Li, Meng-Yu Ba, Weyland Cheng, Hai-Liang Zhu & Yong-Tao Duan. (2021) Cyclopropyl Scaffold: A Generalist for Marketed Drugs. Mini-Reviews in Medicinal Chemistry 21:2, pages 150-170.
Crossref
Hua Yan, Xieraili Tiemuerniyazi, Yangwu Song, Fei Xu & Wei Feng. (2020) Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study. Journal of Cardiothoracic Surgery 15:1.
Crossref
Valeria Gasperi, M. Valeria Catani & Isabella Savini. (2020) Platelet Responses in Cardiovascular Disease: Sex-Related Differences in Nutritional and Pharmacological Interventions. Cardiovascular Therapeutics 2020, pages 1-16.
Crossref
Michelle M. Schreuder, Ricardo Badal, Eric Boersma, Maryam Kavousi, Jolien Roos‐Hesselink, Jorie Versmissen, Loes E. Visser & Jeanine E. Roeters van Lennep. (2020) Efficacy and Safety of High Potent P2Y 12 Inhibitors Prasugrel and Ticagrelor in Patients With Coronary Heart Disease Treated With Dual Antiplatelet Therapy: A Sex‐Specific Systematic Review and Meta‐Analysis . Journal of the American Heart Association 9:4.
Crossref
Piera Capranzano, Bruno Francaviglia & Dominick J. Angiolillo. (2019) Pharmacodynamics During Transition Between Platelet P2Y12 Inhibiting Therapies. Interventional Cardiology Clinics 8:4, pages 321-340.
Crossref
Vivek Karan, Devashish Vyas, Vikram Bohra & Vikram Huded. (2019) Ticagrelor Use in Indian Patients Undergoing Neuroendovascular Procedures: A Single Center Experience. Neurointervention 14:2, pages 125-130.
Crossref
Kyungho Kim & Kwang-Il Park. (2019) A Review of Antiplatelet Activity of Traditional Medicinal Herbs on Integrative Medicine Studies. Evidence-Based Complementary and Alternative Medicine 2019, pages 1-18.
Crossref
Xiaodong Xia, Jiao Li, Xue Liang, Shengjie Zhang, Tong Liu, Jinying Liu, Muhammad Arif & Guangping Li. (2018) Ticagrelor suppresses oxidized low‑density lipoprotein‑induced endothelial cell apoptosis and alleviates atherosclerosis in ApoE‑/‑ mice via downregulation of PCSK9. Molecular Medicine Reports.
Crossref
An Ning Cheng, Yu-Kang Lo, Yi-Sheng Lin, Tswen-Kei Tang, Chun-Hua Hsu, John T.-A. Hsu & Alan Yueh-Luen Lee. (2018) Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach. EBioMedicine 36, pages 241-251.
Crossref
Byambasuren Ganbaatar, Daiju Fukuda, Hotimah Masdan Salim, Sachiko Nishimoto, Kimie Tanaka, Yasutomi Higashikuni, Yoichiro Hirata, Shusuke Yagi, Takeshi Soeki & Masataka Sata. (2018) Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice. Atherosclerosis 275, pages 124-132.
Crossref
Michael S. Lee & Michael T. Tanoue. (2018) Impact of Ticagrelor in Patients With Prior MI and MVD for Reducing Cardiovascular Events. Journal of the American College of Cardiology 71:5, pages 497-498.
Crossref
Habib Haybar & Zeinab Deris Zayeri. (2017) The value of using polymorphisms in anti-platelet therapy. Frontiers in Biology 12:5, pages 349-356.
Crossref
Chaoyan Qin, Jinfeng Zhou, Yuan Gao, Weiming Lai, Cuixia Yang, Yingying Cai, Shuai Chen & Changsheng Du. (2017) Critical Role of P2Y12 Receptor in Regulation of Th17 Differentiation and Experimental Autoimmune Encephalomyelitis Pathogenesis. The Journal of Immunology 199:1, pages 72-81.
Crossref
Joseph M. Sweeny, Dominick J. Angiolillo, Francesco Franchi, Fabiana Rollini, Ron Waksman, Ganesh Raveendran, George Dangas, Naeem D. Khan, Glenn F. Carlson, Yonggang Zhao, Renli Teng & Roxana Mehran. (2017) Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. Journal of the American Heart Association 6:4.
Crossref
Piera Capranzano & Dominick J. Angiolillo. 2017. Interventional Cardiology. Interventional Cardiology 377 388 .
Fabiana Rollini, Francesco Franchi & Dominick Angiolillo. (2017) Oral trans-mucosal administration of ticagrelor: is this really the future?. Thrombosis and Haemostasis 117:05, pages 826-828.
Crossref
Mohamed Rizk, Maha A. Sultan, Elham A. Taha, Ali K. Attia & Youmna M. Abdallah. (2017) Highly Sensitive Carbon Based Sensing Utilizing Titanium Dioxide Nanoparticles and Multiwalled Carbon Nanotubes for Determination of Ticagrelor: Pharmacokinetics Application. Journal of The Electrochemical Society 164:12, pages H770-H778.
Crossref
Elizabeth E. Bollinger, Melissa A. Spera & Daniel L. Raines. (2017) Device-assisted Enteroscopy for Obscure Gastrointestinal Bleeding in the Setting of Thienopyridine Antiplatelet Therapy. Journal of Clinical Gastroenterology 51:1, pages e1-e4.
Crossref
H. G. Du, M. W. Yu, C. E. Deng, C. H. Lu & S. L. Li. (2017) Synthesis, Antiplatelet Aggregation Activity Evaluation and 3D-QSAR of a Series of Novel 6-Alkylamino(Alkoxyl)-2-Propylthio-8-Azapurine Nucleosides. Journal of Heterocyclic Chemistry 54:1, pages 436-449.
Crossref
Tanaji T. Talele. (2016) The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules. Journal of Medicinal Chemistry 59:19, pages 8712-8756.
Crossref
Davide Capodanno, Mark Alberts & Dominick J. Angiolillo. (2016) Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. Nature Reviews Cardiology 13:10, pages 609-622.
Crossref
Yongwhi Park, Francesco Franchi, Fabiana Rollini & Dominick J. Angiolillo. (2016) Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. Trends in Cardiovascular Medicine 26:4, pages 321-334.
Crossref
Dominick J. Angiolillo, Francesco Franchi, Ron Waksman, Joseph M. Sweeny, Ganesh Raveendran, Renli Teng, Yonggang Zhao, Glenn Carlson, Naeem Khan & Roxana Mehran. (2016) Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. Journal of the American College of Cardiology 67:6, pages 603-613.
Crossref
Jung Rae Cho, Fabiana Rollini, Francesco Franchi, Christopher DeGroat, Mona Bhatti, Elizabeth C. Dunn, Elisabetta Ferrante, Ana Muniz-Lozano, Siva Suryadevara, Martin M. Zenni, Luis A. Guzman, Theodore A. Bass & Dominick J. Angiolillo. (2015) Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy. JACC: Cardiovascular Interventions 8:8, pages 1075-1083.
Crossref
Jeremiah P. DeptaDeepak L. Bhatt. (2015) New Approaches to Inhibiting Platelets and Coagulation. Annual Review of Pharmacology and Toxicology 55:1, pages 373-397.
Crossref
Antonio Tello-Montoliu, Eva Jover & Mariano Valdés. (2014) Nuevos antiagregantes plaquetarios en cardiopatía isquémica. Medicina Clínica 143:11, pages 508-514.
Crossref
Carol H. Hu, Jennifer X. Qiao, Ying Han, Tammy C. Wang, Ji Hua, Laura A. Price, Qimin Wu, Hong Shen, Christine S. Huang, Robert Rehfuss, Ruth R. Wexler & Patrick Y.S. Lam. (2014) 2-Amino-1,3,4-thiadiazoles in the 7-hydroxy-N-neopentyl spiropiperidine indolinyl series as potent P2Y1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 24:11, pages 2481-2485.
Crossref
Ricardo A Hanel, Philipp Taussky, Tanya Dixon, David A Miller, Merlie Sapin, Jerah D Nordeen, Rabih G Tawk, Ramon Navarro, Gretchen Johns & William D Freeman. (2014) Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. Journal of NeuroInterventional Surgery 6:4, pages 320-322.
Crossref
Judy W. M. Cheng. (2013) Updates in Antiplatelet Agents Used in Cardiovascular Diseases. Journal of Cardiovascular Pharmacology and Therapeutics 18:6, pages 514-524.
Crossref
Piera Capranzano & Dominick J. Angiolillo. (2013) Basics of Antithrombotic Therapy for Cardiovascular Disease. Interventional Cardiology Clinics 2:4, pages 499-513.
Crossref
D. Capodanno, J.L. Ferreiro & D.J. Angiolillo. (2013) Antiplatelet therapy: new pharmacological agents and changing paradigms. Journal of Thrombosis and Haemostasis 11, pages 316-329.
Crossref
Fabiana Rollini, Francesco Franchi, Ana Muñiz-Lozano & Dominick J Angiolillo. (2013) Platelet Function Profiles in Patients with Diabetes Mellitus. Journal of Cardiovascular Translational Research 6:3, pages 329-345.
Crossref
Shahdad Azmoon & Dominick J. Angiolillo. (2012) Switching antiplatelet regimens: Alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: A review of the literature and practical considerations for the interventional cardiologist. Catheterization and Cardiovascular Interventions 81:2, pages 232-242.
Crossref
D. Sibbing, M. Orban & S. Massberg. (2017) Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome. Hämostaseologie 33:01, pages 9-15.
Crossref
John S. Schroeder, William H. Frishman, John D. Parker, Dominick J. Angiolillo, Christopher Woods & Benjamin M. Scirica. 2013. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease 83 130 .
Jeremiah P. Depta & Deepak L. Bhatt. (2012) Antiplatelet therapy and proton pump inhibition. Current Opinion in Cardiology 27:6, pages 642-650.
Crossref
Antonio Tello-Montoliu & Dominick J. Angiolillo. 2012. Coronary Atherosclerosis. Coronary Atherosclerosis 287 301 .
Fabiana RolliniAntonio Tello-MontoliuDominick J Angiolillo. (2012) Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease. Future Cardiology 8:4, pages 503-511.
Crossref
Guocheng Liu, Jiaxi Xu, Ning Chen, Si Zhang, Zhongren Ding & Hongguang Du. (2012) Synthesis of N6-alkyl(aryl)-2-alkyl(aryl)thioadenosines as antiplatelet agents. European Journal of Medicinal Chemistry 53, pages 114-123.
Crossref
Judy W.M. Cheng. (2012) Ticagrelor: Oral Reversible P2Y12 Receptor Antagonist for the Management of Acute Coronary Syndromes. Clinical Therapeutics 34:6, pages 1209-1220.
Crossref
Harold L. Lazar. (2012) The Year in Review: Surgical Revascularization of Coronary Artery Disease-2011. Journal of Cardiac Surgery 27:3, pages 347-359.
Crossref
Davide Capodanno, Valeria Calvi & Corrado Tamburino. (2012) Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of Cardiovascular Medicine 13:2, pages 162-163.
Crossref
Arun Kalyanasundaram & A. Michael Lincoff. (2011) Managing adverse effects and drug–drug interactions of antiplatelet agents. Nature Reviews Cardiology 8:10, pages 592-600.
Crossref
Antonio Tello-Montoliu, Masafumi Ueno & Dominick J Angiolillo. (2011) Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. Future Cardiology 7:3, pages 381-402.
Crossref
Emma D. Deeks. (2011) Ticagrelor. Drugs 71:7, pages 909-933.
Crossref
David J. Schneider. (2011) Mechanisms Potentially Contributing to the Reduction in Mortality Associated With Ticagrelor Therapy. Journal of the American College of Cardiology 57:6, pages 685-687.
Crossref
Masafumi Ueno, Murali Kodali, Antonio Tello-Montoliu & Dominick Joseph Angiolillo. (2011) Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease. Journal of Atherosclerosis and Thrombosis 18:6, pages 431-442.
Crossref
Neena S. AbrahamMark A. HlatkyElliott M. AntmanDeepak L. BhattDavid J. BjorkmanCraig B. ClarkCurt D. FurbergDavid A. JohnsonCharles J. KahiLoren LaineKenneth W. MahaffeyEamonn M. QuigleyJames ScheimanLaurence S. SperlingGordon F. Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation 122:24, pages 2619-2633.
Crossref
Neena S Abraham, Mark A Hlatky, Elliott M Antman, Deepak L Bhatt, David J Bjorkman, Craig B Clark, Curt D Furberg, David A Johnson, Charles J Kahi, Loren Laine, Kenneth W Mahaffey, Eamonn M Quigley, James Scheiman, Laurence S Sperling & Gordon F Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. American Journal of Gastroenterology 105:12, pages 2533-2549.
Crossref
Neena S. Abraham, Mark A. Hlatky, Elliott M. Antman, Deepak L. Bhatt, David J. Bjorkman, Craig B. Clark, Curt D. Furberg, David A. Johnson, Charles J. Kahi, Loren Laine, Kenneth W. Mahaffey, Eamonn M. Quigley, James Scheiman, Laurence S. Sperling & Gordon F. Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology 56:24, pages 2051-2066.
Crossref
José Luis Ferreiro, Ángel R Cequier & Dominick J Angiolillo. (2010) Review article: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. Diabetes and Vascular Disease Research 7:4, pages 274-288.
Crossref
David Vivas & Dominick J. Angiolillo. (2010) Platelet P2Y12 Receptor Inhibition. American Journal Cardiovascular Drugs 10:4, pages 217-226.
Crossref
Masafumi Ueno, Sunil V Rao & Dominick J Angiolillo. (2010) Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiology 6:4, pages 445-453.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.